Trump sets tariffs on pharmaceuticals, trucks, furniture

The new levies, ranging from 25% to 100%, will go into effect Oct. 1, the president said Thursday.

By Phil Neuffer • Sept. 25, 2025

Lilly’s oral SERD gets FDA nod in advanced breast cancer

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable type of hormone therapy.

By Ben Fidler • Sept. 25, 2025

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

Lilly stops trial of muscle-sparing obesity drug

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in people taking weight loss medicines. 

By Jonathan Gardner • Sept. 25, 2025

Sanofi Ventures banks $625M to back young biotechs, digital health startups

The French pharma’s venture arm will use the funds to back companies working in immunology, neurology, rare diseases and vaccines.

By Gwendolyn Wu • Sept. 24, 2025

FDA, in unusual step, aims to repurpose old GSK drug as autism treatment

After reviewing existing published literature, the agency initiated the approval of Wellcovorin — which GSK stopped selling more than two decades ago — for a condition associated with autism.

By Kristin Jensen • Sept. 23, 2025

Pfizer buys back into obesity drug chase with $4.9B Metsera deal

The deal ends a short run as a publicly traded company for Metsera, which is being sold for more than double its IPO price amid enthusiasm for its weight loss medicines.

By Jonathan Gardner • Sept. 22, 2025

CDC panel recommends splitting measles, varicella shots

The committee reconvened Friday to re-do a vote on coverage of the combined MMRV shot through the Vaccines for Children program, citing panelists’ confusion the day before. 

By Jonathan Gardner • Updated Sept. 19, 2025

GSK ups US investment with $30B spending plan

The British drugmaker’s commitment comes as some of its pharma peers question their U.K. presence amid a widening row there over pricing polices.

By Ned Pagliarulo • Sept. 17, 2025

Lilly, Novo showcase new obesity drug data; Fasenra falls short in COPD

Lilly claimed success in a head-to-head trial of oral GLP-1 drugs. Elsewhere, Novo planned a new weight loss trial and an AI-focused startup raised its second “megaround.”

By BioPharma Dive staff • Sept. 17, 2025

Working smarter: best practices for thermal modeling in cold chain packaging design

Smarter cold chain design starts with thermal modeling—learn best practices here.

Sept. 15, 2025

Lilly to give biotech startups access to AI tools

Insitro, Firefly Bio and Superluminal Medicines are among the first participants in Lilly’s “TuneLabs” platform, which the pharma says can help young drugmakers while training its own models.

By Gwendolyn Wu • Sept. 9, 2025

Novartis to gain heart drug in $1.4B deal for Tourmaline Bio

Tourmaline recently unveiled mid-stage trial data for its anti-inflammatory drug, which is ready for Novartis to advance into Phase 3 testing for heart disease.

By Delilah Alvarado • Sept. 9, 2025

Pfizer, BioNTech showcase new data supporting COVID booster

The companies said their updated shot spurred an increase in neutralizing antibodies against currently circulating strains, answering calls for more corroborating evidence.

By Delilah Alvarado • Sept. 8, 2025

Amgen to invest $600M in new US center; Sanofi drug for ITP approved

The new "science and innovation center" will be built at Amgen's headquarters in Thousand Oaks, California. Elsewhere, Wayrilz became the first BTK blocker cleared for immune thrombocytopenia.

By BioPharma Dive staff • Sept. 2, 2025

Amylyx drug comes up short; Sanofi names new CMO

AMX0035 missed the goals of a study in progressive supranuclear palsy. Elsewhere, Novartis and BioArctic struck a deal, and Genentech started building its first East Coast factory.

By BioPharma Dive staff • Aug. 27, 2025

Lilly to submit obesity pill after hitting goal in third late-stage trial

In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior testing.

By Jonathan Gardner • Aug. 26, 2025

FDA cancels adcomm on Biohaven drug; Catalent lays off staff

Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 staff at a gene therapy facility.

By BioPharma Dive staff • Aug. 22, 2025

Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could that potentially widen access to CAR-T treatment.

By Jonathan Gardner • Aug. 21, 2025

Lilly searching for new neuro chief as White set to retire

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly Neuroscience at the end of December.

By Ned Pagliarulo • Aug. 20, 2025

Kennedy’s mRNA cuts could set US science back, experts warn

Scientists say HHS’ decision to defund mRNA vaccine research will leave the country less prepared for pandemics, and make it harder to invest in companies advancing the technology.

By Delilah Alvarado • Aug. 18, 2025

Navigating the oncology patent cliff: Strategic imperatives for big pharma

Key cancer drugs lose exclusivity soon—who’s ready to withstand the oncology patent cliff?

By Andreas Dimakakos, Director of Scientific Insights, PhD, MBA, PMP ; and Elena Hilario Martinez, Customer Success Associate • Aug. 18, 2025

The unexpected medication that could revolutionize the treatment of Alzheimer’s disease

A new wave of Alzheimer’s research suggests semaglutide, widely known for diabetes and weight loss, could also slow cognitive decline—two major trials aim to reveal the truth by 2025.

Aug. 18, 2025

Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.

By BioPharma Dive staff • Aug. 15, 2025

Merck KGaA ventures into new territory in the US

Miguel Fernández Alcalde, head of Merck KGaA’s U.S. arm, aims to “double down” on innovation. The company’s recent SpringWorks deal is just a start.

By Alexandra Pecci • Aug. 15, 2025

Pfizer looks to expand ADC use after positive bladder cancer data

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify for chemotherapy.

By Jonathan Gardner • Aug. 12, 2025